Tags

Type your tag names separated by a space and hit enter

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.
Neuropsychopharmacology 2018; 43(1):142-154N

Abstract

The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are >550 chemical compounds and >100 phytocannabinoids isolated from cannabis, including Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is thought to produce the main psychoactive effects of cannabis, while CBD does not appear to have similar effects. Studies conflict as to whether CBD attenuates or exacerbates the behavioral and cognitive effects of THC. This includes effects of CBD on THC-induced anxiety, psychosis, and cognitive deficits. In this article, we review the available evidence on the pharmacology and behavioral interactions of THC and CBD from preclinical and human studies, particularly with reference to anxiety and psychosis-like symptoms. Both THC and CBD, as well as other cannabinoid molecules, are currently being evaluated for medicinal purposes, separately and in combination. Future cannabis-related policy decisions should include consideration of scientific findings, including the individual and interactive effects of CBD and THC.

Authors+Show Affiliations

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. VA Connecticut Healthcare System, West Haven, CT, USA.Department of Neuroscience; The Scripps Research Institute, La Jolla, CA, USA.VA Connecticut Healthcare System, West Haven, CT, USA.Department of Neuroscience; The Scripps Research Institute, La Jolla, CA, USA.Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. VA Connecticut Healthcare System, West Haven, CT, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28875990

Citation

Boggs, Douglas L., et al. "Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 43, no. 1, 2018, pp. 142-154.
Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142-154.
Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2018). Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 43(1), pp. 142-154. doi:10.1038/npp.2017.209.
Boggs DL, et al. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142-154. PubMed PMID: 28875990.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. AU - Boggs,Douglas L, AU - Nguyen,Jacques D, AU - Morgenson,Daralyn, AU - Taffe,Michael A, AU - Ranganathan,Mohini, Y1 - 2017/09/06/ PY - 2017/04/04/received PY - 2017/08/30/revised PY - 2017/08/31/accepted PY - 2017/9/7/pubmed PY - 2018/7/27/medline PY - 2017/9/7/entrez SP - 142 EP - 154 JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology JO - Neuropsychopharmacology VL - 43 IS - 1 N2 - The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are >550 chemical compounds and >100 phytocannabinoids isolated from cannabis, including Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is thought to produce the main psychoactive effects of cannabis, while CBD does not appear to have similar effects. Studies conflict as to whether CBD attenuates or exacerbates the behavioral and cognitive effects of THC. This includes effects of CBD on THC-induced anxiety, psychosis, and cognitive deficits. In this article, we review the available evidence on the pharmacology and behavioral interactions of THC and CBD from preclinical and human studies, particularly with reference to anxiety and psychosis-like symptoms. Both THC and CBD, as well as other cannabinoid molecules, are currently being evaluated for medicinal purposes, separately and in combination. Future cannabis-related policy decisions should include consideration of scientific findings, including the individual and interactive effects of CBD and THC. SN - 1740-634X UR - https://www.unboundmedicine.com/medline/citation/28875990/Clinical_and_Preclinical_Evidence_for_Functional_Interactions_of_Cannabidiol_and_Δ9_Tetrahydrocannabinol_ L2 - http://dx.doi.org/10.1038/npp.2017.209 DB - PRIME DP - Unbound Medicine ER -